- Advanced search
- Immuno Portal
- Malaria Portal
|No information available.|
|Summary of Clinical Use|
|Following evaluation in Phase III clinical trial for MM, which tested various combinations of lenalidomide, dexamethasone or bortezomib ± elotuzumab [3-4], the US FDA approved the elotuzumab/lenalidomide/dexamethasone combination in late 2015. Use is indicated for MM patients who have received one to three prior therapies.
In the European Union elotuzumab has had orphan drug designation since August 2012, for the treatment of MM.
|Mechanism Of Action and Pharmacodynamic Effects|
|CS1 is present in particularly high levels on the plasma cells from patients with MM . Elotuzumab engagement of CS1 effectively activates the body's immune system to attack and kill MM cells by inducing antibody-dependent cellular cytotoxicity (ADCC) against them .|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)